Jianyu Weng

3.3k total citations · 1 hit paper
84 papers, 2.1k citations indexed

About

Jianyu Weng is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Jianyu Weng has authored 84 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Hematology, 28 papers in Genetics and 25 papers in Molecular Biology. Recurrent topics in Jianyu Weng's work include Acute Myeloid Leukemia Research (28 papers), Hematopoietic Stem Cell Transplantation (17 papers) and CAR-T cell therapy research (14 papers). Jianyu Weng is often cited by papers focused on Acute Myeloid Leukemia Research (28 papers), Hematopoietic Stem Cell Transplantation (17 papers) and CAR-T cell therapy research (14 papers). Jianyu Weng collaborates with scholars based in China, United States and United Kingdom. Jianyu Weng's co-authors include Xin Du, Peilong Lai, Chang He, Duanqing Pei, Tian Zhou, Zenan Yuan, Suxia Geng, Suijing Wu, Liyan Guo and Xiaomei Chen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jianyu Weng

79 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Challenges and advances in clinical applications of mesenchymal stromal cells

2021 476 citations Jianyu Weng, Xin Du et al. Journal of Hematology & Oncology profile →

Peers

Jianyu Weng

GENET

IMMUN

ONCOL

HEMAT

Xin Du China

Matti Korhonen Finland

Mehrdad Abedi United States

Carlijn Voermans Netherlands

Belén Blanco Spain

Stefan Wöhrer Austria

Kazuya Sato Japan

Peilong Lai China

Enrique J. Andreu Spain

Stephen Grupp United States

Xin Du China

Jianyu Weng

849 ×1.0

539 ×0.8

GENET

449 ×0.9

IMMUN

512 ×1.0

ONCOL

259 ×0.6

HEMAT

Citations per year, relative to Jianyu Weng Jianyu Weng (= 1×) peers Xin Du

Countries citing papers authored by Jianyu Weng

Since Specialization

Citations

This map shows the geographic impact of Jianyu Weng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianyu Weng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianyu Weng more than expected).

Fields of papers citing papers by Jianyu Weng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianyu Weng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianyu Weng. The network helps show where Jianyu Weng may publish in the future.

Co-authorship network of co-authors of Jianyu Weng

This figure shows the co-authorship network connecting the top 25 collaborators of Jianyu Weng. A scholar is included among the top collaborators of Jianyu Weng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianyu Weng. Jianyu Weng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Huafeng, Xudong Wei, Qian Jiang, et al.. (2024). Safety and efficacy of lisaftoclax, a novel BCL-2 inhibitor, in combination with azacitidine in patients with treatment-naïve or relapsed or refractory acute myeloid leukemia.. Journal of Clinical Oncology. 42(16_suppl). 6541–6541. 1 indexed citations

Yang, Lin, Weiya Zhang, Jianyu Weng, et al.. (2024). Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. Journal of Hematology & Oncology. 17(1). 105–105. 38 indexed citations

Wu, Miao, Yawen Wang, Yulian Wang, et al.. (2023). Mesenchymal stem cells reversibly de-differentiate myofibroblasts to fibroblast-like cells by inhibiting the TGF-β-SMAD2/3 pathway. Molecular Medicine. 29(1). 59–59. 14 indexed citations

Deng, Chengxin, Ping Wu, Xin Huang, et al.. (2023). Outcomes of intermediate or high‐risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience. Clinical and Translational Science. 17(1). e13711–e13711. 1 indexed citations

Chen, Xiaomei, Yulian Wang, Xin Huang, et al.. (2023). Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice. International Immunopharmacology. 117. 109746–109746. 3 indexed citations

Wang, Jundan, et al.. (2023). Disruption of mitochondrial oxidative phosphorylation by chidamide eradicates leukemic cells in AML. Clinical & Translational Oncology. 25(6). 1805–1820. 4 indexed citations

Wang, Jinghua, et al.. (2022). Incidence and effect of secondary cardiac amyloidosis on outcomes of patients with t(11;14) multiple myeloma. Frontiers in Cardiovascular Medicine. 9. 994384–994384.

Zhou, Lijuan, Yulian Wang, Chao Li, et al.. (2022). Deep learning-based transcriptome model predicts survival of T-cell acute lymphoblastic leukemia. Frontiers in Oncology. 12. 1057153–1057153. 1 indexed citations

Wang, Jinghua, Zewei Zhuo, Yanjun Wang, et al.. (2022). Identification and Validation of a Prognostic Risk-Scoring Model Based on Ferroptosis-Associated Cluster in Acute Myeloid Leukemia. Frontiers in Cell and Developmental Biology. 9. 800267–800267. 28 indexed citations

10.

Wu, Depei, Jianyu Weng, Junling Zhuang, et al.. (2022). Phase 1b/3 Pharmacokinetics and Safety Study of Intravenous Posaconazole in Adult Asian Participants at High Risk for Invasive Fungal Infections. Advances in Therapy. 39(4). 1697–1710. 1 indexed citations

11.

Wang, Jinghua, Weida Wang, Hao Chen, et al.. (2021). C‐Type Lectin‐Like Molecule‐1 as a Biomarker for Diagnosis and Prognosis in Acute Myeloid Leukemia: A Preliminary Study. BioMed Research International. 2021(1). 6643948–6643948. 12 indexed citations

12.

Huang, Xin, Cunte Chen, Suxia Geng, et al.. (2021). Lower BCL11B expression is associated with adverse clinical outcome for patients with myelodysplastic syndrome. Biomarker Research. 9(1). 46–46. 8 indexed citations

13.

Chen, Xiaofang, Ningyu Li, Jianyu Weng, & Xin Du. (2021). Senescent Mesenchymal Stem Cells in Myelodysplastic Syndrome: Functional Alterations, Molecular Mechanisms, and Therapeutic Strategies. Frontiers in Cell and Developmental Biology. 8. 617466–617466. 7 indexed citations

14.

Zou, Yunfeng, Rong Ying, Zhe Chen, et al.. (2020). Effects of Huaier Extract on Ameliorating Colitis-Associated Colorectal Tumorigenesis in Mice. SHILAP Revista de lepidopterología. 1 indexed citations

15.

Luo, Chengwei, Peilong Lai, Lin Wei, et al.. (2020). von Willebrand Factor as a Predictor for Transplant-Associated Thrombotic Microangiopathy. Clinical and Applied Thrombosis/Hemostasis. 26. 2873291212–2873291212. 10 indexed citations

16.

Wang, Yulian, Peilong Lai, Xiaomei Chen, et al.. (2017). Attenuation of cGVHD by C5a/C5aR blockade is associated with increased frequency of Treg. Scientific Reports. 7(1). 3603–3603. 9 indexed citations

17.

Geng, Suxia, Jianyu Weng, Shaohua Chen, et al.. (2015). Abnormalities in the T Cell Receptor Vδ Repertoire and Foxp3 Expression in Refractory Anemia with Ringed Sideroblasts. DNA and Cell Biology. 34(9). 588–595. 2 indexed citations

18.

Wu, Ping, Suxia Geng, Jianyu Weng, et al.. (2014). The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome. Leukemia Research. 39(2). 216–220. 26 indexed citations

19.

Weng, Jianyu, Peilong Lai, Ling Wei, et al.. (2012). Bortezomib Modulates Regulatory T Cell Subpopulations in the Process of Acute Graft-Versus-Host Disease. Clinical Laboratory. 59(01+02/2013). 51–8. 7 indexed citations

20.

Zhong, Liye, Tianhao Liu, Yangqiu Li, et al.. (2009). [Serum proteomics in patients with RAEB myelodysplastic syndromes].. PubMed. 29(9). 1799–801. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact